News and Announcements
Battery Materials HPA Coating Plant Pre-Feasibility Study Commenced
- Published March 31, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Click here to view the ASX announcement
About Altech Chemicals (ASX: ATC)
Altech Chemicals Limited (Altech/the Company) is aiming to become one of the world’s leading suppliers of 99.99% (4N) high purity alumina (Al2O3)(HPA) through the construction and operation of a 4,500tpa HPA manufacturing plant at Johor, Malaysia. Feedstock for the plant will be sourced from the Company’s 100%-owned kaolin deposit at Meckering, Western Australia and shipped to Malaysia. Construction has commenced at the HPA plant site and is by German engineering firm SMS group. Stage-1 early works were handed-over in October 2019 and Stage 2 in July 2020. Altech’s HPA production process is to employ conventional “off-the-shelf” plant and equipment to extract HPA using a hydrochloric acid (HCl) based process. Production costs are anticipated to be considerably lower than established HPA producers – in the bottom quartile of the cost curve. The Project is a high margin, high value proposition.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
